Navigation Links
Newsbriefs from the July issue of the journal Chest
Date:7/4/2011

COMBINATION ANTITHROMBOTIC THERAPY MAY INCREASE BLEEDING RISK

A new study suggests that the use of combination antithrombotic therapy may increase the risk of clinically relevant bleeding in patients with atrial fibrillation (AF). Researchers from the United Kingdom, the Netherlands, and France compared outcomes in 3,728 patients with AF receiving anticoagulation alone and 848 patients with AF receiving combination antithrombotic therapy (anticoagulant and antiplatelet therapy). Results showed that patients receiving combination therapy had a 2.3-fold increased risk of clinically relevant bleeding compared with anticoagulation therapy alone. Combination antithrombotic therapy also does not appear to reduce the risk of stroke. Results suggest that combination antithrombotic treatment is justified only in patients where the benefit of adding antiplatelet therapy to anticoagulant therapy outweighs bleeding risk. This article is published in the July issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians: Chest. 2011;140(1):146-155.


IDENTIFYING PULMONARY ARTERIAL HYPERTENSION EARLY REMAINS PROBLEMATIC

One in five patients diagnosed with pulmonary arterial hypertension (PAH) in the United States report symptoms for more than 2 years before diagnosis. PAH is a progressive and fatal disorder, and the disease is often advanced when recognized, especially in younger patients. Researchers from Intermountain Medical Center, the University of California, University of Pennsylvania, Baylor College of Medicine, Boston University, and Mayo Clinic studied 2,967 adult patients enrolled in the Registry to Evaluate Early Long-term PAH Disease Management (REVEAL), for an 18-month period. In 21.1% of patients, symptoms were experienced for more than two years before PAH was recognized. History of obstructive airways disease and sleep apnea were independently associated with delayed PAH recognition. Despite progress in understanding the cellular and genetic basis of PAH, researchers found that the onset of PAH before age 36 years was associated with the greatest likelihood of delayed disease recognition, especially in individuals with histories of common respiratory disorders. This article is published in the July issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians: Chest. 2011;140(1):19-26.


INDACATEROL MAY REDUCE EXACERBATIONS IN PATIENTS WITH MODERATE TO SEVERE COPD

New research shows that indacaterol is effective and well tolerated for patients with moderate to severe chronic obstructive pulmonary disease (COPD). Researchers at the University Health Network, Asthma and Airway Centre, in Toronto, ON, Canada; the University of Nebraska Medical Center; and Novartis evaluated the safety and tolerability of indacaterol, a once-daily, inhaled β2-agonist, compared with a placebo in 415 patients with moderate to severe COPD. Over a 1-year period, researchers found that therapy with indacaterol led to significant reductions in COPD exacerbations and as-needed albuterol use, and it was well tolerated. This article is published in the July issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians: Chest. 2011;140(1):68-75.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. Newsbriefs from the April issue of the journal Chest
2. Emotional, Behavioral Issues Affect Many Kids in Foster Care
3. Breast Cancer Plus Other Health Issues Linked to Worse Outcomes
4. FDA Issues New Rules on Sunscreens
5. Ovarian cancer cells bully their way through tissue
6. Chest journal news briefs -- June 2011 issue
7. Hartford Program issues geriatric social work awards, forms VA partnership
8. ASGE and SHEA issue updated multisociety guideline on reprocessing flexible gastrointestinal endoscopes
9. Childhood Cancer Therapies Tied to Gastrointestinal Issues
10. MetLife Foundations grant bolsters media coverage for aging issues
11. Experts Issue Top 5 List for Better Primary Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: